EA201891164A1 - Композиции и способы получения белковых микрочастиц - Google Patents

Композиции и способы получения белковых микрочастиц

Info

Publication number
EA201891164A1
EA201891164A1 EA201891164A EA201891164A EA201891164A1 EA 201891164 A1 EA201891164 A1 EA 201891164A1 EA 201891164 A EA201891164 A EA 201891164A EA 201891164 A EA201891164 A EA 201891164A EA 201891164 A1 EA201891164 A1 EA 201891164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
micron
obtaining protein
protein microparticles
Prior art date
Application number
EA201891164A
Other languages
English (en)
Inventor
Филип Брадники
Хантер Чен
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57708873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201891164(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201891164A1 publication Critical patent/EA201891164A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предлагаются частицы микронного размера, содержащие терапевтический белок и, необязательно, вспомогательные вещества, и покрытие из биосовместимого и биоразлагаемого полимера, а также способы получения и применения этих микрочастиц. Терапевтический белок, приготовленный в виде фармацевтического порошка из частиц микронного размера, сохраняет стабильность в течение длительного периода времени и является пригодным для нанесения полимерного покрытия для замедленного высвобождения, а также сохраняет стабильность в физиологических условиях.
EA201891164A 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц EA201891164A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268259P 2015-12-16 2015-12-16
PCT/US2016/067280 WO2017106716A1 (en) 2015-12-16 2016-12-16 Compositions and methods of manufacturing protein microparticles

Publications (1)

Publication Number Publication Date
EA201891164A1 true EA201891164A1 (ru) 2018-11-30

Family

ID=57708873

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201891164A EA201891164A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц
EA202192290A EA202192290A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202192290A EA202192290A1 (ru) 2015-12-16 2016-12-16 Композиции и способы получения белковых микрочастиц

Country Status (22)

Country Link
US (1) US20200022917A1 (ru)
EP (2) EP4059492B1 (ru)
JP (2) JP7185526B2 (ru)
KR (1) KR20180088836A (ru)
CN (2) CN108366968B (ru)
AU (2) AU2016369557B2 (ru)
BR (1) BR112018010743B1 (ru)
CA (1) CA3003654A1 (ru)
CL (2) CL2018001623A1 (ru)
CO (1) CO2018005920A2 (ru)
DK (1) DK3389636T3 (ru)
EA (2) EA201891164A1 (ru)
ES (1) ES2927348T3 (ru)
HK (1) HK1251461A1 (ru)
HU (1) HUE060148T2 (ru)
IL (3) IL302211A (ru)
MX (1) MX2018005384A (ru)
PH (2) PH12018500830A1 (ru)
PL (1) PL3389636T3 (ru)
SG (2) SG11201803197UA (ru)
WO (1) WO2017106716A1 (ru)
ZA (1) ZA201802706B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111132695A (zh) * 2017-08-18 2020-05-08 里珍纳龙药品有限公司 分析样品基质中蛋白变异体的成像毛细管等电聚焦
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
CN113365609A (zh) 2019-01-31 2021-09-07 伊勒卓菲公司 颗粒形成和形态
AU2020344675A1 (en) 2019-09-13 2022-03-31 Elektrofi, Inc. Compositions and methods for the delivery of therapeutic biologics for treatment of disease
CN114980839A (zh) * 2019-11-15 2022-08-30 蚕丝科技有限公司 丝蛋白的稳定制剂
KR20220104797A (ko) * 2019-11-25 2022-07-26 리제너론 파마슈티칼스 인코포레이티드 비수성 에멀전을 이용한 지속 방출 제형
WO2021158959A2 (en) * 2020-02-07 2021-08-12 Elektrofi, Inc. Peptide particles and methods of formation
AU2021385363A1 (en) * 2020-11-25 2023-06-08 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210529A (en) 1974-12-26 1980-07-01 Midwest Research Institute Blood compatible polymers and applications thereof
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4764364A (en) 1986-02-25 1988-08-16 S R I International Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US5104221A (en) 1989-03-03 1992-04-14 Coulter Electronics Of New England, Inc. Particle size analysis utilizing polarization intensity differential scattering
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6019968A (en) * 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US6927004B2 (en) 2002-03-08 2005-08-09 Asml Netherlands B.V. Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
JP4627425B2 (ja) 2004-09-29 2011-02-09 本田技研工業株式会社 無段変速機の変速制御装置
AU2005319382B2 (en) 2004-12-21 2011-04-07 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
PL2100618T3 (pl) 2005-06-17 2014-07-31 Imclone Llc Przeciwciało anty-PDGFR alfa do zastosowania w leczeniu przerzutowego raka kości
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
SI2364691T1 (sl) * 2006-06-16 2013-08-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
MX2009011226A (es) 2007-04-17 2010-04-01 Imclone Llc Inhibidores especificos pdgfrbeta.
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
CA2716882A1 (en) 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions and methods for inhibiting pdgfr-beta and vegf-a
WO2010104973A1 (en) * 2009-03-11 2010-09-16 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2803998A1 (en) 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
AR087305A1 (es) * 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
BR112014011915B1 (pt) 2011-11-18 2022-08-30 Regeneron Pharmaceuticals, Inc Métodos para fabricar uma composição farmacêutica de liberação prolongada e para fornecer um revestimento de liberação prolongada, e, formulação de liberação prolongada
EP3427721A1 (en) 2012-05-18 2019-01-16 Genentech, Inc. High-concentration monoclonal antibody formulations
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
EP3389636B1 (en) 2022-07-20
DK3389636T3 (da) 2022-09-19
JP2019504825A (ja) 2019-02-21
EA202192290A1 (ru) 2022-02-28
BR112018010743A2 (pt) 2018-11-21
EP4059492A1 (en) 2022-09-21
EP4059492B1 (en) 2024-04-17
IL286601B2 (en) 2023-09-01
AU2016369557A1 (en) 2018-06-07
AU2016369557B2 (en) 2022-10-20
BR112018010743B1 (pt) 2024-02-15
US20200022917A1 (en) 2020-01-23
SG10202007834VA (en) 2020-09-29
EP3389636A1 (en) 2018-10-24
CA3003654A1 (en) 2017-06-22
IL286601A (en) 2021-10-31
SG11201803197UA (en) 2018-05-30
WO2017106716A1 (en) 2017-06-22
AU2022291549A1 (en) 2023-02-02
CN108366968A (zh) 2018-08-03
CL2018001623A1 (es) 2018-07-20
PH12021550603A1 (en) 2021-11-03
PH12018500830A1 (en) 2018-10-29
CL2023002345A1 (es) 2024-03-15
CN114404371A (zh) 2022-04-29
IL259204A (en) 2018-07-31
IL259204B (en) 2021-10-31
MX2018005384A (es) 2018-08-16
KR20180088836A (ko) 2018-08-07
CN108366968B (zh) 2022-02-18
IL302211A (en) 2023-06-01
JP2022185057A (ja) 2022-12-13
CO2018005920A2 (es) 2018-06-20
BR112018010743A8 (pt) 2019-02-26
PL3389636T3 (pl) 2022-11-28
HUE060148T2 (hu) 2023-02-28
ES2927348T3 (es) 2022-11-04
IL286601B1 (en) 2023-05-01
HK1251461A1 (zh) 2019-02-01
ZA201802706B (en) 2023-12-20
JP7185526B2 (ja) 2022-12-07

Similar Documents

Publication Publication Date Title
EA201891164A1 (ru) Композиции и способы получения белковых микрочастиц
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2017005259A (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas.
MX2019000382A (es) Microparticulas de polimero y proteina.
IL245117A0 (en) Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
EA201501024A1 (ru) Составы с замедленным высвобождением, содержащие колхицин, и способы их применения
PH12015502535B1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
NZ729417A (en) Compositions and methods for enhancing healing and regeneration of bone and soft tissue
MY176631A (en) Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors
EP3634437A4 (en) COMPOSITIONS AND PROCEDURES FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
ZA201906548B (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EP3265165A4 (en) Implant applicators and methods of administering implants
MX2021003908A (es) Polipeptidos de accion prolongada y metodos para su produccion y administracion.
EA201500032A1 (ru) Композиция в виде пасты для ухода за стомой
EP3733831A4 (en) ARTIFICIAL TISSUE INFUSION DEVICE AND DRUG EVALUATION METHOD USING ARTIFICIAL TISSUE
EA201992844A1 (ru) Новые пероральные составы на основе белиностата
EA202191570A1 (ru) Композиции для доставки терапевтических средств, способы их применения и получения
PL414229A1 (pl) Kompozycja farmaceutyczna w postaci kserożelu do leczenia choroby Leśniowskiego-Crohna i sposób otrzymywania kompozycji farmaceutycznej